Federated Hermes Inc. Has $243.13 Million Stock Holdings in Cencora, Inc. $COR

Federated Hermes Inc. increased its stake in shares of Cencora, Inc. (NYSE:COR) by 13.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 777,945 shares of the company’s stock after buying an additional 89,289 shares during the period. Federated Hermes Inc. owned 0.40% of Cencora worth $243,131,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC lifted its holdings in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the last quarter. Copia Wealth Management lifted its holdings in Cencora by 505.0% during the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock worth $38,000 after purchasing an additional 101 shares during the last quarter. Caldwell Trust Co bought a new stake in Cencora in the 2nd quarter valued at $46,000. Finally, Salomon & Ludwin LLC grew its holdings in Cencora by 638.1% in the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after buying an additional 134 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on COR. UBS Group lifted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. TD Cowen lifted their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. boosted their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $393.08.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,316 shares of company stock worth $7,151,265 over the last 90 days. Insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Shares of Cencora stock opened at $356.15 on Wednesday. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The company has a market cap of $69.09 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The company has a 50 day moving average of $348.17 and a 200-day moving average of $323.06. Cencora, Inc. has a 1-year low of $237.71 and a 1-year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s payout ratio is 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.